GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Contineum Therapeutics Inc (NAS:CTNM) » Definitions » Net Policyholder Benefits/Claims

Contineum Therapeutics (Contineum Therapeutics) Net Policyholder Benefits/Claims


View and export this data going back to 2024. Start your Free Trial

What is Contineum Therapeutics Net Policyholder Benefits/Claims?

Net Policyholder Benefits/Claims only applies to insurance companies.


Contineum Therapeutics (Contineum Therapeutics) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
10578 Science Center Drive, Suite 200, San Diego, CA, USA, 92121
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.